The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): Final results of the TAMRAD trial translational study.
Isabelle Treilleux
No relevant relationships to disclose
Monica Arnedos
No relevant relationships to disclose
Claire Cropet
No relevant relationships to disclose
Jean-Marc Ferrero
No relevant relationships to disclose
Sophie Abadie Lacourtoisie
No relevant relationships to disclose
Dominique Spaeth
Consultant or Advisory Role - Novartis
Christelle Levy
No relevant relationships to disclose
Eric Legouffe
No relevant relationships to disclose
Eric Pujade-Lauraine
No relevant relationships to disclose
Quing WANG
No relevant relationships to disclose
Thomas Bachelot
Consultant or Advisory Role - Novartis
Research Funding - Novartis